Kathryn Russo comments on the DOT's final rule to add semisynthetic-opioids to drug testing panel to combat opioid epidemic in "Semisynthetic-opioid testing may expand with DOT on board," published by Business Insurance.
Subscription may be required to view article
Read Article at Business Insurance